TLSI Historical PE Ratio Notes

— TriSalus Life Sciences (TLSI) is a clinical-stage medical technology company focused on developing innovative therapies & targeted delivery systems for treating solid tumors, especially in the liver and pancreas. Their platform integrates device-based drug delivery with immunotherapy, aiming to enhance treatment efficacy & overcome limitations of traditional systemic therapies. TLSI operates in a highly dynamic & capital-intensive sector, with revenue typically dependent on successful clinical milestones and commercialization efforts. As an investor reviewing historical P/E ratio data, it's important to recognize that companies like TriSalus often exhibit negative or highly volatile earnings (the denominator in the P/E ratio), especially prior to significant regulatory approvals and widespread adoption. This can lead to either undefined, exceptionally high, or even negative historical P/E ratios. Market expectations for future growth, clinical trial outcomes, & regulatory progress are often factored into TLSI's stock price well before notable profitability is achieved. Consequently, historical P/E ratios for TLSI may not reflect conventional valuation benchmarks, but rather capture evolving market sentiment in response to both the company's pipeline developments and the broader biotech sector's risk/reward dynamics.

On this page we presented the TLSI Historical PE Ratio information for TriSalus Life Sciences' stock. The average TLSI historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 38.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average TLSI historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this TLSI historical PE result, against the recent PE: when this page was posted on 9/9/2026, the most recent closing price for TLSI had been 4.76, and the most recent quarterly earnings result, annualized, was 0.12. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent TLSI PE on 9/9/2026 based on annualized quarterly EPS was 39.7. Based on TLSI's history, that recent PE is elevated relative to the historical average, with the recent PE 4.5% higher than the historical average PE across our data set for TriSalus Life Sciences.

For self directed investors doing their due diligence on TLSI or any other given stock, valuation analysis for TLSI can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate TriSalus Life Sciences PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for TLSI. Thanks for visiting, and the next time you need to research TLSI Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.